The Observers team at Abcuro plays a critical role in monitoring and documenting the progress of clinical studies for ABC008, ensuring data accuracy and regulatory compliance. They meticulously record patient responses, treatment outcomes, and any adverse effects, providing essential data to guide the development of the anti-KLRG1 antibody therapy for inclusion body myositis (IBM).